United States News Todas as matérias

HUTCHMED (NASDAQ:HCM) initiated a global Phase Ia clinical trial of HMPL-A830 in patients with advanced solid tumors, with the first patient receiving a dose in China on September 24, 2026.

QIAGEN (NYSE:QGEN) received U.S. Food and Drug Administration clearance for its QIAstat-Dx BCID GN Plus AMR Panel, expanding access to its bloodstream infection testing portfolio for U.S. laboratories.

Burford Capital (NYSE:BUR) said it has a financial entitlement in the Taction Technology v. Apple patent case, where a jury awarded the plaintiff $5.7 billion after the market closed on September 25, 2026.

Tandem Diabetes Care (NASDAQ:TNDM) announced that Tandem Mobi, its automated insulin delivery system, is now available in 12 countries outside the United States, with the company accepting orders and shipping to eligible customers.

Planet Labs PBC (NYSE:PL) announced that Pelican-12, an updated second-generation high-resolution Pelican satellite, arrived at Cape Canaveral Space Force Station ahead of its planned launch aboard SpaceX’s Bandwagon-5 rideshare mission.

Astrotech (NASDAQ:ASTC) reported fiscal 2026 revenue of $913,000 for the year ended June 30, 2026, as the company continued commercial deployment of its analytical technology platforms.

Nektar Therapeutics (NASDAQ:NKTR) received a jury verdict awarding the company $90 million in damages after a court found Eli Lilly (NYSE:LLY) breached the implied covenant of good faith and fair dealing related to a prior rezpegaldesleukin license agreement.

Firefly Neuroscience (NASDAQ:AIFF) and NeuroSigma announced a partnership to introduce NeuroSigma’s Monarch eTNS System to clinicians using Firefly’s Evoke brain-function assessment platform.

XCF Global (NASDAQ:SAFX) reported more than $10 million in August revenue from renewable diesel shipped from its Reno facility after the site restarted operations in July 2026.

Johnson & Johnson (NYSE:JNJ) reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR study evaluating adults with active psoriatic arthritis and MRI-confirmed axial inflammation.

Legend Biotech (NASDAQ:LEGN) reported five-year results from the Phase 2 CARTITUDE-2 Cohort A study showing that 10 of 20 patients treated with a single CARVYKTI infusion remained alive and progression-free without further anti-myeloma treatment.

Ocugen (NASDAQ:OCGN) announced that OCU400 received provisional approval and priority designation in The Bahamas for the treatment of retinitis pigmentosa, an inherited eye disorder.

C4 Therapeutics (NASDAQ:CCCC) presented new biomarker data from two Phase 1 multiple myeloma combination trials evaluating cemsidomide, including studies with dexamethasone and elranatamab.

Fate Therapeutics (NASDAQ:FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support the Phase 2 RECLAIM-LN clinical trial evaluating FT819, an off-the-shelf CAR T-cell therapy.

Madison Dearborn Partners agreed to acquire The Marygold Companies (NYSE:MGLD) in an all-cash transaction that values each outstanding share at $2.00 and will take the financial services company private.

AstraZeneca (NASDAQ:AZN) received U.S. Food and Drug Administration Priority Review for its supplemental Biologics License Application for IMFINZI (durvalumab) combined with enfortumab vedotin in patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy.

Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.

Merck (NYSE:MRK) and Eisai received U.S. Food and Drug Administration approval for the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) to treat adults with advanced clear cell renal cell carcinoma after PD-1 or PD-L1 inhibitor therapy.

Duke Energy (NYSE:DUK) appointed Joyce Mullen to its board of directors effective September 28, 2026, with Mullen joining the Audit Committee and Operations and Nuclear Oversight Committee.

Addex Therapeutics (NASDAQ:ADXN) announced it regained full global rights to its GABAB positive allosteric modulator assets from Indivior UK, including a development candidate previously selected under their research collaboration.

Johnson Outdoors (NASDAQ:JOUT) announced that its board of directors approved a quarterly cash dividend of $0.33 per Class A share and $0.30 per Class B share, payable on October 23, 2026.

Vertical Aerospace (NYSE:EVTL) opened a dedicated Aircraft Assembly Centre at its Cotswold Airport Flight Test Centre, adding 60,000 square feet of manufacturing space to support the development and production of its Valo electric vertical take-off and landing aircraft.

Akamai Technologies (NASDAQ:AKAM) shares rose 21% premarket after the company signed an $11.6 billion, seven-year cloud services agreement with AI company Anthropic, with the deal including a warrant that could allow Anthropic to acquire a stake of up to 5% in Akamai.

WhiteHawk Minerals Corp. (NYSE:WHK) announced the closing of approximately $111.8 million in acquisitions, including the $105 million purchase of Marcellus, Utica, and Haynesville Shale natural gas mineral and royalty assets from San Jacinto Minerals II.